Skip to main content
Clinical Trials/KCT0003056
KCT0003056
Recruiting
未知

?/?a clinical research to evaluate the safety and effectiveness of EBI-H (Auto-derived activated lymphocyte) for subacute above medium severity and chronic atopic dermatitis patients

GNSBIO0 sites23 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Diseases of the skin and subcutaneous tissue
Sponsor
GNSBIO
Enrollment
23
Status
Recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional Study
Sex
All

Investigators

Sponsor
GNSBIO

Eligibility Criteria

Inclusion Criteria

  • 1\) A person under the age of 65 and above the age of 19 years old
  • 2\) The proper atopic dermatitis patients according to Hanifin and Rajka diagnostic criteria
  • 3\) The subacute and chronic atopic dermatitis patients with atopic dermatitis symptoms that have lasted for more than 6 months at least
  • 4\) The subacute above medium severity atopic dermatitis patients (EASI score over 7 points)
  • 5\) The specific patients who have not been improved through the general treatment or can not use the pre\-developed medicine because of concern about potential side\-effect
  • 6\) A fertile woman who is negative in the pregnancy test and agrees to use the permitted manner of contraception during clinical research
  • 7\) A patient who has voluntarily agreed to participate in this clinical research with written consent

Exclusion Criteria

  • 1\) A patient who have other uncontrolled diseases including infection above medium severity and bleeding
  • 2\) A person who has positive in HBV, HCV, HIV and VDRL
  • 3\) A patient whose blood pressure cannot be controlled under SBP 140mmHg or DBP 90mmHg with injecting antihypertensive drug, during screening
  • 4\) An uncontrolled patient with diabetes whose HbA1c values is over 8\.0 during screening
  • 5\) An asthmatic patient who needs high concentration of inhaled steroids with 2nd modifier or systemic steroid therapy or uncontrolled patient with those treatment
  • 6\) A patient who has skin autoimmune disease including psoriasis and systemic autoimmune diseases (Erythema lupus, rheumatism arthritis, severe muscle failure, etc)
  • 7\) A person who uses systemic adrenocortical hormone drug, systemic immune suppressor/immune modulator, high potency topical adrenocortical hormone drug (WHO Group I\~III), topical immune modulator and biological drug within 4 weeks before screening
  • 8\) A patient who took topical adrenocortical hormone drug (WHO Group IV, V), systemic photochemotherapy and systemic antibiotic within 2 weeks before screening
  • 9\) A patient who took antihistamine through oral or injection methods within a week before participating in the clinical research
  • 10\) A patient who have taken a prohibited combinatory drug or have to take a prohibited combinatory drug during clinical research

Outcomes

Primary Outcomes

Not specified

Similar Trials